However, the JPML created a distinct MDL specifically for the vision-related claims
At the same time, multiple blockbuster GLP-1 therapies are already on the market (Ozempic, Wegovy, and Mounjaro), with numerous next-generation analogues and combination incretin therapies currently in development
The risk of yo-yo effects, where patients lose muscle on the drug and regain fat after stopping, is a real concern
GLP-1 receptor agonists act primarily by enhancing postprandial insulin secretion and suppressing glucagon release, leading to improved glycemic control (8)
Whether youre ordering our animal protein meals or plant-based options, youll get macro-balanced, protein-packed dishes
J Neurosurg Anesthesiol 36(4): 278282